CBGL (Cannabis Global) Debt-to-Equity: 1.32 (As of May. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cannabis Global Debt-to-Equity?

Cannabis Global CBGL Debt-to-Equity is 1.32 as of May. 2022.

Cannabis Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2022 was $3.06 Mil. Cannabis Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2022 was $1.17 Mil. Cannabis Global's Total Stockholders Equity for the quarter that ended in May. 2022 was $3.21 Mil. Cannabis Global's debt to equity for the quarter that ended in May. 2022 was 1.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cannabis Global's Debt-to-Equity or its related term are showing as below:

CBGL's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Cannabis Global  (OTCPK:CBGL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cannabis Global Debt-to-Equity Related Terms

Cannabis Global Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Cannabis Global's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Global Debt-to-Equity Chart

Cannabis Global Annual Data
Trend Aug12 Aug13 Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.79 -0.69 0.77 -1.65 -1.81

Cannabis Global Quarterly Data
Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.22 -1.81 6.95 1.21 1.32

CBGL vs MILC, BBBT, GCAN: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Global Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Global's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cannabis Global's Debt-to-Equity falls into.


Cannabis Global Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cannabis Global's Debt to Equity Ratio for the fiscal year that ended in Aug. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.77 + 1.236) / -2.212
=-1.81

Cannabis Global's Debt to Equity Ratio for the quarter that ended in May. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.058 + 1.174) / 3.213
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 1.32 mean?
Cannabis Global (CBGL) has a Debt-to-Equity of 1.32 as of May. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cannabis Global and its competitors.
Is Cannabis Global's Debt-to-Equity too high?
Cannabis Global's current Debt-to-Equity is 1.32. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Cannabis Global's value of 1.32 is 388.9% above this industry median.
How does Cannabis Global's Debt-to-Equity compare to MILC and BBBT?
Cannabis Global's Debt-to-Equity of 1.32 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. Cannabis Global's value of 1.32 is 388.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabis Global's current Debt-to-Equity of 1.32 is 388.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cannabis Global and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Global's current Debt-to-Equity is 1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Global stock overvalued right now?
Cannabis Global (CBGL) has a current Debt-to-Equity of 1.32. The current Debt-to-Equity is 1.32 and 388.9% above the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cannabis Global (CBGL), the current Debt-to-Equity is 1.32 as of May. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Global Business Description

Address 520 S Grand Avenue, Suite 320, Los Angeles, CA, USA, 90071
Cannabis Global Inc manufactures and distributes various cannabis products via its majority ownership of Natural Plant Extract, Inc is developing the Ethos Comply Bag, and generally conducts research and development in the areas of hemp, cannabis and consumer food goods. The company also have an active research and development program focused on creating and commercializing engineered technologies that deliver hemp extracts and cannabinoids to the human body. Its product includes cannabis flower packaged in various weights, cannabis Pre-rolls, cannabis edible products.